Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 23Ovarian Neoplasms 18Neoplasm Metastasis 12Triple Negative Breast Neoplasms 9Prostatic Neoplasms 9Pancreatic Neoplasms 8Neoplasms 8Fallopian Tube Neoplasms 6Squamous Cell Carcinoma of Head and Neck 4Advanced Solid Tumors 4Small Cell Lung Carcinoma 3Recurrence 3Head and Neck Neoplasms 3Endometrial Neoplasms 3Carcinoma, Squamous Cell 3Solid Tumors 2Sarcoma 2Neuroendocrine Tumors 2Lymphoma 2Lung Neoplasms 2Hodgkin Disease 2Fanconi Anemia, Complementation Group D1 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumours 2Advanced Solid Tumor 2Advanced Cancer 2Triple Negative Metastatic Breast Cancer 1Thymoma 1Thrombocytosis 1Solid Tumor 1

Interventions

olaparib 1decitabine and cedazuridine drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × BRCA1 Mutation × olaparib × Clear all
NCT06177171 2026-05-27

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

University of California, San Francisco

Phase 1 Recruiting
18 enrolled

BRCA1 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡